|The full article is available to subscribers||Subscriber Login|
The FDA has approved Liletta, an intrauterine device (IUD) that releases the synthetic progestin levonorgestrel, for prevention of pregnancy for up to 3 years. The fourth IUD to be approved in the US, and the third that releases levonorgestrel, Liletta is comarketed by Actavis and Medicines360, a nonprofit women's health pharmaceutical company. The wholesale cost of Liletta is similar to that of other IUDs (see Table 1), but the manufacturer offers programs that significantly reduce the cost for commercially-insured patients and clinics serving low-income women.1
OTHER IUDs — IUDs provide convenient, long-term contraception and a rapid return to fertility after removal. ParaGard T 380A, a copper-containing IUD, Mirena, which contains 52 mg of levonorgestrel, and Skyla, which contains 13.5 mg... more
- Liletta Patient Savings Program. Patient eligibility requirements. Terms and conditions available at: www.lilettacard.com. Accessed June 25, 2015.
- Choice of contraceptives. Treat Guidel Med Lett 2010; 8:89.
- A new low-dose levonorgestrel-releasing IUD (Skyla). Med Lett Drugs Ther 2013; 55:21.
- DL Eisenberg et al. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. Contraception 2015; 92:10.
- American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No 121: Long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol 2011; 118:184.